N-oxide Dopamine Stabilizers for Cardiovascular Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dopamine receptor stabilizers and modulators face challenges with low oral bioavailability due to rapid metabolism in the gastrointestinal tract and liver, leading to reduced therapeutic efficacy and increased side effects, including cardiovascular risks such as QT interval prolongation and Torsades de Pointes.
Innovation Solution
Development of N-oxide and di-N-oxide derivatives of dopamine receptor stabilizers/modulators with specific chemical structures that undergo reductive bioactivation, reducing cardiovascular side effects and enhancing oral bioavailability by avoiding first-pass metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopamine receptor stabilizers are administered orally, then therapeutic treatment is provided, but rapid metabolism in the gastrointestinal tract and liver reduces bioavailability and increases side effects
Solution Approach 1:
The patent applies preliminary action by converting the dopamine receptor stabilizer into an N-oxide derivative before administration. This pre-modified compound undergoes reductive bioactivation in the body to release the active parent compound, allowing it to bypass first-pass metabolism and achieve higher systemic bioavailability while maintaining therapeutic efficacy.
2Reliability
If dopamine receptor stabilizers are administered orally, then therapeutic treatment is provided, but cardiovascular side effects such as QT interval prolongation and Torsades de Pointes increase
Solution Approach 1:
The N-oxide derivative serves as an intermediary compound that delivers the active dopamine receptor stabilizer indirectly. This mediator approach allows the active compound to be released in situ after reductive bioactivation, avoiding direct administration and associated cardiovascular side effects while maintaining therapeutic benefit.
3Reliability
If N-oxide derivatives are used to improve bioavailability, then oral bioavailability and duration of action are improved, but chemical structure complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure through N-oxidation, which is a straightforward chemical transformation that adds an oxygen atom to the nitrogen atom. This single parameter change (oxidation state) significantly improves bioavailability and duration of action without substantially complicating the overall molecular structure or synthesis pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The N-oxide and di-N-oxide derivatives exhibit prolonged action, improved bioavailability, and decreased risk of serious cardiovascular side effects, providing effective treatment for neurological and psychiatric disorders with enhanced therapeutic potential.
Implementation Method 1
N-oxide and di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved therapeutic potential, improved oral bioavailability, improved side-effects profile
Data Source
AI summary
A compound having the general formulawherein A is selected from the group consisting ofto the formation of a compound of the general formula (1)and a compound of the general formula (2)respectively, and pharmaceutically acceptable salts thereof, whereinR1 is a member selected from the group consisting of CF3, OSO2CF3, OSO2CH3, SOR4, SO2R4, COR4, CN, OR4, NO2, CONHR4, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br and I, wherein R4 is as defined below;R2 is a member selected from the group consisting of H, F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, NH2, SOmCF3, O(CH2)mCF3, SO2N(R4)2, CH═NOR4, COCOOR4, COCOON(R4)2, (C1-C8)alkyl, (C3-C8)cykloalkyl, CH2OR4, CH2(R4)2, NR4SO2CF3, NO2, at phenyl at positions 2, 4, 5 or 6, wherein x and R4 are as defined below;R3 is a member selected from the group consisting of hydrogen, CF3, CH2CF3, (C1-C8)alkyl, (C3-C8)cykloalkyl, (C4-C9)cycloalkylmethyl, (C2-C8)alkenyl, (C2-C8)alkynyl, 3,3,3-tri-fluoropropyl, 4,4,4-trifluorobutyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, phenylethyl, 2-thiopheneethyl and 3-thiopheneethyl;R4 is a member selected from the group consisting of hydrogen, CF3, CH2CF3, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C4-C9)cycloalkylmethyl, (C2-C8)alkenyl, (C2-C8)alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2-tetrahydrofurane and 3-tetrahydrofurane;X is selected from the group consisting of N and sp3-hybridized C;Y is selected from the group consisting of O and, when R3 represents H, OH;Z is selected from the group consisting of H and OH when X is sp3-hybridized C or Z represents O or an electronic lone-pair when X is N;the dashed line represents a bond when X is sp2-hybridized C or is absent when X is N;m is an integer 1 or 2;n is an integer 1-3;provided thatwhen n in Formula 1 is 2, R1 is SO2CH3 and R2 is H R3 does not represent n-propyl.The invention also relates to a pharmaceutical preparation containing said compound, the use of said compound for the manufacture of a pharmaceutical composition and a method for the treatment of a disorder in the central nervous system of a patient using said compound.